Advanced clinical trials of dendritic cell vaccines in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-07-27 / J. Investig. Med. 2020 Jul;Exosomes in Tumor Immunotherapy: Mediator, Drug Carrier, and Prognostic Biomarker
/in International Publications /von 2020-07-23 / Adv Biosyst 2020 Jul;:e2000061Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
/in International Publications, IOZK Veröffentlichungen /von 2020-07-23 / Biomedicines 2020 Jul;8(8)Modulated Electro-Hyperthermia Resolves Radioresistance of Panc1 Pancreas Adenocarcinoma and Promotes DNA Damage and Apoptosis In Vitro
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2020-07-19 / Int J Mol Sci 2020 Jul;21(14)Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy
/in Dendritic Cells, International Publications /von 2020-07-14 / Pharmaceutics 2020 Jul;12(7)Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-07-13 / Immunol. Invest. 2020 Jul;:1-18Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2020-07-07 / Cancers (Basel) 2020 Jul;12(7)Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2020-07-04 / Cancer Immunol. Immunother. 2020 Jul;Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2020-07-02 / Signal Transduct Target Ther 2020 Jul;5(1):114IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de